直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 117810
タイトル別表記
Daptomycin-related Musculoskeletal Adverse Events and Statin Use
著者
中馬, 真幸 Tokushima University|Asahikawa Medical University
Nakamoto, Aki Tokushima University
Bando, Takashi Tokushima University
Kondo, Yutaka Juntendo University
Asada, Mizuho Tokyo Medical and Dental University
座間味, 義人 Tokushima University|Okayama University KAKEN研究者をさがす
武智, 研志 Tokushima University|Matsuyama University
Miyata, Koji Tokushima University
Yoshioka, Toshihiko Tokushima University
Tasaki, Yoshikazu Asahikawa Medical University
キーワード
daptomycin
statin
musculoskeletal adverse event
meta-analysis
disproportionality analysis
資料タイプ
学術雑誌論文
抄録
Background. There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs.
Methods. We used a mixed approach that combines 2 methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population.
Results. In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83; 95% confidence interval [CI]: 1.43–10.26) but not DAP-related myopathy (OR: 1.72; 95% CI: .95–3.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69; 95% CI: 4.31–7.51) and rhabdomyolysis (ROR: 5.77; 95% CI: 4.33–7.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis.
Conclusion. The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety.
掲載誌名
Clinical Infectious Diseases
ISSN
10584838
15376591
cat書誌ID
AA10822963
出版者
Infectious Diseases Society of America|Oxford University Press
75
8
開始ページ
1416
終了ページ
1422
発行日
2022-03-09
権利情報
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
病院
医学系
薬学系